BIA welcomes new deal between Vertex and NHS England
Steve Bates OBE, Chief Executive of the BIA said: “It’s fantastic to see the NHS and Vertex strike a lightning quick deal to enable NHS cystic fibrosis patients to access this important breakthrough therapy.
"The speed of this deal will not only improve the health outcomes of many people with cystic fibrosis, but also sends a clear message to the global life sciences industry that the UK is a great place to develop, trial, and launch innovative medicines."
Notes to Editors
1. For more information please contact Shannon Quinney, Communications Executive on firstname.lastname@example.org or 07864 902930.
2. The announcement took place during today's Health and Social Care Committee. More detail can be found here.
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.